pSivida acquires Icon, rebrands to EyePoint

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT; ASX:PVA) (formerly pSivida Corp.) acquired Icon Bioscience Inc. (Newark, Calif.) and rebranded under a new name and ticker.

EyePoint gained Icon's Dexycu dexamethasone intraocular suspension 9%, which received FDA approval in February to treat postoperative inflammation. Dexycu is a sustained-release formulation of dexamethasone delivered using Verisome technology (see BioCentury, Feb. 23)...